Dr Reddy's Lab re-launces over-the-counter Naproxen Sodium Tablets in US market; Stock gains 1%

Dr Reddy's Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.

Aug 04, 2021 12:08 IST India Infoline News Service

Dr Reddys Laboratories
Dr Reddy's Laboratories announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

"The re-launch of Dr Reddy's Naproxen Sodium Tablets, 220 mg (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products," says Marc Kikuchi, CEO, North America Generics, Dr Reddy's Laboratories. "This launch represents our continued endeavour to leverage our strong capabilities and vertically integrated supply chain on key APIs like naproxen to ensure a consistent and reliable supply of finished products for our customers and patients."

OTC Naproxen Sodium Tablets USP, 220 mg is an over-the-counter nonsteroidal anti-inflammatory drug (NSAID) for use as a pain reliever and fever reducer. It temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold; it is also used to temporarily reduce fever.

Naproxen Sodium Tablets USP, 220 mg, had U.S. retail sales of approximately $316 million as of July 2021 according to IRI*.

Dr Reddy's Naproxen Sodium Tablets USP, 220 mg, will be available in multiple-pack sizes to allow consumers a variety of purchasing options.

Aleve is a trademark of Bayer HealthCare LLC.

At around 12.27 pm, Dr Reddy's was trading at Rs4784.70 per piece

Related Story

Open Free Demat Account (Rs699)